Press Releases

Oxygen-concentrating wound dressing delivers a breath of fresh air to hard-to heal wounds

28-Mar-07

Archimed launches Oxyzyme™, an active hydrogel wound dressing that transports dissolved oxygen to the wound.

Archimed launches Oxyzyme™, an active hydrogel wound dressing that transports dissolved oxygen to the wound.

Archimed, a Bedford (UK) based biotechnology firm, has today announced the launch of a new range of oxygen-concentrating hydrogel wound dressings - Oxyzyme™ - that transfer dissolved oxygen to the surface of hard-to-heal chronic wounds, such as ulcers or post-operative wounds.

Oxygen is essential to life. In wound healing it plays a key role by supporting tissue regeneration and repair, by inhibiting anaerobic bacteria and supporting the body’s natural defence mechanisms.

Prof. Paul Davis, founder of Archimed said: “The complex wound healing process demands large amounts of energy, which equates to a large demand for oxygen.  The importance of adequate oxygen levels during the wound healing process is well recognised.  Traditional wisdom is that wounds need to breathe, but leaving the wound open to the air can cause excessive drying and crusting (scab formation) which can delay epithelialisation and exclude oxygen from the wound. Keeping the wound covered and moist helps prevent this, but can restrict the wound’s access to the oxygen levels needed to support healing. Oxyzyme™ resolves this dilemma by creating a moist wound healing environment that is oxygen-rich, to assist the body’s natural healing process.”

Oxygen has been used to aid wound healing for a number of years, primarily through Hyperbaric Oxygen Therapy (HBO). However for various reasons it has not been widely adopted.  Oxyzyme™ wound dressings are as easy to use as conventional dressings, are comfortable for the patient, and provide oxygen balance where it is needed most.

Oxyzyme™ uses advanced biochemistry to work like a molecular pump, drawing in oxygen from the atmosphere and transporting it to the surface of the wound.  Oxyzyme™ has two components: an advanced hydrogel sheet containing glucose that is placed directly onto the wound, and an enzyme sheet that contains glucose oxidase, a natural enzyme found, for example, in honey.

The biochemistry is triggered when the enzyme sheet is placed on top of the glucose-containing gel.  Atmospheric oxygen at the surface of the enzyme sheet is trapped by the glucose oxidase and converted to a low level of hydrogen peroxide.  This creates an oxygen gradient that allows more oxygen to be drawn into the dressing.  The hydrogen peroxide is freely soluble in the aqueous medium of the dressing (unlike oxygen) and can readily diffuse to the wound, where it is instantly converted back to oxygen.  Some of the hydrogen peroxide also reacts with iodide within the dressing, to produce a small amount of iodine (evidenced by the colour of the dressing changing to amber or gold).  Iodine has long been known for its antibacterial properties, and helps to produce an environment that is hostile to bacteria.

Clinical trials in 2005, conducted by Prof. Gary Sibbald (head of the Toronto Wound Healing Centers, Canada, and a world leading authority in wound care) found that long term wounds, some of which had been present for a year or more, showed visible improvement in just four weeks.  Further trials in the UK (in Cardiff and Aberdeen) in 2006 showed that two thirds of hard-to-heal wounds significantly improved after six weeks. 

Prof. Sibbald said: “The Oxyzyme™ platform is a fundamentally new approach to moist wound healing and shows exciting promise in difficult to heal chronic wounds.”

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Latest Clinical Articles

Clinical Review - Renal colic

Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more

Clinical Review - Stroke

By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more

Sjogren's syndrome

Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more

Show all clinical articles

Latest News

GPC demands 4% practice income rise

The GPC has demanded a 4% rise in GMS income for 2009/10 to combat soaring expenses and inflation. Read more

Calculator allows GPs to work out if they will be contract winners

The GPC has published an online calculator to allow practices to work out if they will be winners or... Read more

NHS chief urges PCTs to 'interfere less' with PBC

PCTs should interfere less in practice-based commissioning (PBC), the NHS chief executive has warned... Read more

Babies born before peak flu season at higher asthma risk

Children born four months before peak flu season have a greater risk of developing asthma than those... Read more

MHRA issues faulty defibrillator warning

Defibrillators manufactured by Medtronic may fail to work because of a faulty internal cable, the Me... Read more

MIMS Product News

New drug - Intelence

Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more

New drug - Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more

Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more

Jobs

 

Job of the Week